Printer Friendly

MEDICARE CHANGES, SIDE EFFECTS OF DRUG BODE WELL FOR IMEX

 MEDICARE CHANGES, SIDE EFFECTS OF DRUG BODE WELL FOR IMEX
 GOLDEN, Colo., Nov. 27 /PRNewswire/ -- Imex Medical Systems Inc. (NASDAQ: IMEX), reports that interest has accelerated for its IMEXLAB 9000 following two events; the recent findings of a major new study of a cholesterol-lowering drug that is proving to reduce fat deposits in coronary arteries, and because of the firming up of Medicare reimbursements for diagnosis of circulation problems.
 Lovastatin, sold by prescription under the name Mevacor, is manufactured by Merck & Company of Rahway, N.J. In a new report made public last week, a single drug - for the first time - appears to shrink and reverse the build-up of fatty deposits in arteries, a process known as atherosclerosis. Imex manufactures and markets the IMEXLAB 9000 used to non-invasively diagnose peripheral arteries for atherosclerosis.
 Also, on Nov. 25, Medicare released the final rule for payment for physician's services (RBRVS) beginning Jan. 1, 1992. This new rule replaces "prevailing charges" with a set fee schedule for examinations, diagnosis and treatment, including fees paid for diagnoses made with products such as the IMEXLAB 9000.
 "We're excited about the developments of Mevacor and RBRVS payments and think they bode well for Imex," said Dennis Newman, president and chief executive officer of Imex. "Our phones are ringing. The effects of Mevacor and other new drugs should increase physician and consumer awareness that atherosclerosis can be reversed in many cases without surgery. Combined with the new fee schedule for vascular testing, which seems to provide a fair and reasonable return for the physician's investment of time and money, we expect a positive effect in the long run on our sales."
 Imex's revolutionary IMEXLAB 9000 can catch the process of atherosclerosis at an early stage and alert doctors to a potential problem by analyzing a patient's blood flow for disruptions, he added.
 "The early warning diagnostic capabilities of the IMEXLAB 9000 make it possible to identify a high percentage of certain circulatory conditions soon enough to take preventive measures that can enhance the patient's quality of life and even avoid surgery," said Newman.
 Cardiovascular disease is still by far the leading killer in the United States, and according to the United Stroke Foundation, more than 500,000 strokes occur each year, many of which could be prevented by early diagnosis and treatment. The cost of treatment for stroke victims exceeds $14 billion each year.
 Nearly one million Americans are taking lovastatin. As part of a two-year study, some participants were given a placebo and others were given lovastatin. The study carried with it an optional two-year extension, but it was not continued. An independent safety monitoring committee said it would not be ethical to continue to give some participants a placebo rather than lovastatin.
 Many doctors were under the belief that the buildup of plaque advanced un-halted until its conclusion - blocked coronary and other arteries. The deposits build up over years to narrow the arteries and promote the formation of blockages that impede and eventually stop blood flow, killing heart muscle cells and causing a heart attack.
 Imex reported sales of $7,888,792 in fiscal 1991, up 26 percent from a year ago. Earnings also rose to $308,801 or $.05 per share.
 Founded in 1976, Imex Medical Systems manufactures and markets medical instrumentation that complements the major trends in health care including cost containment, the move to outpatient care, and earlier awareness, diagnosis and treatment of cardiovascular disease.
 -0- 11/27/91
 /CONTACT: Dennis Newman of Imex Medical Systems, 303-431-9400; or Mike Jirik, of Carl Thompson Associates, 303-494-5472, for Imex Medical Systems/
 (IMEX) CO: Imex Medical Systems Inc. ST: Colorado IN: MTC SU:


MC -- DV001 -- 7643 11/27/91 09:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 27, 1991
Words:617
Previous Article:KISSIMMEE UTILITY AUTHORITY, FLA. REVENUE BONDS RATED 'A' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:TOCOR II AND CENTOCOR FILE UNIT OFFERING
Topics:


Related Articles
IMEX MEDICAL SYSTEMS ANNOUNCES SIGNIFICANTLY INCREASED SALES FOR FISCAL SECOND QUARTER
IMEX MEDICAL SYSTEMS ANNOUNCES SIGNIFICANTLY INCREASED SALES AND PROFITS FOR THIRD QUARTER
IMEX MEDICAL SYSTEMS INTRODUCES FIRST MODULAR DIAGNOSTIC WORKSTATION WITH NEW HOLTER/ABP SYSTEM
IMEX INTRODUCES LOW-COST 'PIPE CHECK KIT' TO TEST FOR PERIPHERAL ARTERIAL DISEASE (PAD)
VASCULAR TESTING INDUSTRY UNITES TO FORM THE ASSOCIATION FOR COST-EFFECTIVE CARDIOVASCULAR TECHNOLOGY
IMEX MEDICAL SYSTEMS REPORTS INCREASED EARNINGS FOR SECOND QUARTER AND FIRST HALF OF FISCAL 1994
IMEX MEDICAL SYSTEMS REPORTS SALES AND FINANCIAL RESULTS FOR FISCAL 1995 FIRST QUARTER
IMEX MEDICAL SYSTEMS REPORTS SALES AND FINANCIAL RESULTS FOR FISCAL 1995 SECOND QUARTER
Advocacy Organizations Call for Medicare Patient Protections in Letter To Members of Congress.
ScriptSave Applies for Medicare Endorsement of National Prescription Drug Discount Card; With More Than 10 Years of Experience Providing Discount...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters